Haemophilia

Gouri Pandey, FDA
ProImmune REVEAL® Class II HLA-Peptide Binding Assay used to identify potential potential FVIII epitopes that increase the risk of FVIII inhibitors in African-American Haemophilia A patients compared with Caucasians

Katherine High, The Children’s Hospital of Philadelphia
Pro5® MHC Pentamers used in conjunction with ProPresent® Antigen Presentation Assays to identify MHC class I epitopes in AAV vectors that trigger cytotoxic T cell responses when presented by hepatocytes